Incyte Corp. (INCY)
115.30
-1.84
(-1.57%)
USD |
NASDAQ |
Oct 02, 16:00
115.30
0.00 (0.00%)
After-Hours: 20:00
Incyte EPS Diluted (Quarterly) : 2.812 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.812 |
| March 31, 2026 | 1.467 |
| December 31, 2025 | 1.462 |
| September 30, 2025 | 2.106 |
| June 30, 2025 | 2.038 |
| March 31, 2025 | 0.7982 |
| December 31, 2024 | 1.019 |
| September 30, 2024 | 0.5436 |
| June 30, 2024 | -2.038 |
| March 31, 2024 | 0.7462 |
| December 31, 2023 | 0.8892 |
| September 30, 2023 | 0.7573 |
| June 30, 2023 | 0.9021 |
| March 31, 2023 | 0.0962 |
| December 31, 2022 | 0.1266 |
| September 30, 2022 | 0.5031 |
| June 30, 2022 | 0.7218 |
| March 31, 2022 | 0.1704 |
| December 31, 2021 | 2.54 |
| September 30, 2021 | 0.8177 |
| June 30, 2021 | 0.6725 |
| March 31, 2021 | 0.2413 |
| December 31, 2020 | 0.6774 |
| September 30, 2020 | -0.0695 |
| June 30, 2020 | 1.317 |
| Date | Value |
|---|---|
| March 31, 2020 | -3.325 |
| December 31, 2019 | 0.5079 |
| September 30, 2019 | 0.589 |
| June 30, 2019 | 0.4843 |
| March 31, 2019 | 0.47 |
| December 31, 2018 | 0.32 |
| September 30, 2018 | 0.14 |
| June 30, 2018 | 0.24 |
| March 31, 2018 | -0.19 |
| December 31, 2017 | -0.7087 |
| September 30, 2017 | 0.17 |
| June 30, 2017 | -0.06 |
| March 31, 2017 | -0.96 |
| December 31, 2016 | 0.05 |
| September 30, 2016 | 0.19 |
| June 30, 2016 | 0.18 |
| March 31, 2016 | 0.12 |
| December 31, 2015 | 0.29 |
| September 30, 2015 | -0.22 |
| June 30, 2015 | 0.05 |
| March 31, 2015 | -0.11 |
| December 31, 2014 | -0.22 |
| September 30, 2014 | 0.33 |
| June 30, 2014 | -0.22 |
| March 31, 2014 | -0.21 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 12.23 |
| Mirum Pharmaceuticals, Inc. | -1.061 |
| Vertex Pharmaceuticals, Inc. | 4.310 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| AbbVie, Inc. | 2.033 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 585.60M |
| Revenue (Quarterly) | 1.674B |
| Total Expenses (Quarterly) | 1.088B |
| Enterprise Value | 18.68B |
| Gross Profit Margin (Quarterly) | 92.57% |
| Profit Margin (Quarterly) | 34.98% |
| Earnings Yield | 6.81% |
| Operating Earnings Yield | 7.77% |
| Normalized Earnings Yield | 6.912 |